Sequence-Enabled Reassembly of β-Lactamase (SEER-LAC):  A Sensitive Method for the Detection of Double-Stranded DNA

This work describes the development of a new methodology for the detection of specific double-stranded DNA sequences. We previously showed that two inactive fragments of green fluorescent protein, each coupled to engineered zinc finger DNA-binding proteins, were able to reassemble an active reporter...

Full description

Saved in:
Bibliographic Details
Published inBiochemistry (Easton) Vol. 45; no. 11; pp. 3620 - 3625
Main Authors Ooi, Aik T, Stains, Cliff I, Ghosh, Indraneel, Segal, David J
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 21.03.2006
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:This work describes the development of a new methodology for the detection of specific double-stranded DNA sequences. We previously showed that two inactive fragments of green fluorescent protein, each coupled to engineered zinc finger DNA-binding proteins, were able to reassemble an active reporter complex in the presence of a predefined DNA sequence. This system, designated sequence-enabled reassembly (SEER), was demonstrated in vitro to produce a DNA-concentration-dependent signal. Here we endow the SEER system with catalytic capability using the reporter enzyme TEM-1 β-lacatamase. This system could distinguish target DNA from nontarget DNA in less than 5 min, representing a more than 1000-fold improvement over our previous SEER design. A single base-pair substitution in the DNA binding sequence reduced the signal to nearly background levels. Substitution of a different custom zinc finger DNA-binding domain produced a signal only on the new cognate target. Signal intensity was not affected by genomic DNA when present in equal mass to the target DNA. These results present SEER as a rapid and sensitive method for the detection of double-stranded DNA sequences.
Bibliography:ark:/67375/TPS-N9XJ12WQ-9
istex:3477C36CE09E3702088349254B215D9AB09AAA19
D.S. was supported by the American Cancer Society grant IRG7400125 and the NIH grant P50CA95060. C.I.S. was supported by an NIH training grant.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
AUTHOR EMAIL ADDRESSES: segal@pharmacy.arizona.edu, ghosh@email.arizona.edu
TO WHOM CORRESPONDENCE SHOULD BE ADDRESSED: David J. Segal, Tel: 530-754-9134, Fax: 530-754-9658, E-mail: djsegal@ucdavis.edu Indraneel Ghosh, Tel: 520-621-6331, E-mail: ghosh@email.arizona.edu
PRESENT ADDRESS: Department of Pharmacology/Genome Center University of California, Davis Davis, CA 95616
ISSN:0006-2960
1520-4995
DOI:10.1021/bi0517032